FDA approves Sun Pharma’s Coreg CR generic
MUMBAI — The Food and Drug Administration has approved Sun Pharma’s generic of Coreg CR (carvedilol phosphate) extended-release capsules. The drug is a beta blocker indicated to mild-to-sever chronic heart failure, left ventricular dysfuntion following myocardial infarction and hypertension.
Sun Pharma’s generic will be available in 10-, 20-, 40- and 80-mg dosage strengths. The product had U.S. sales of roughly $208 million for the 12 months ended August 2017, according to QuintilesIMS data.